Status:

RECRUITING

What is the Optimal Antithrombotic Strategy in Patients With Atrial Fibrillation Undergoing PCI?

Lead Sponsor:

St. Antonius Hospital

Collaborating Sponsors:

Daiichi Sankyo

Conditions:

Acute Coronary Syndrome

Myocardial Infarction

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

The optimal antithrombotic management in patients with coronary artery disease (CAD) and concomitant atrial fibrillation (AF) is unknown. AF patients are treated with oral anticoagulation (OAC) to pre...

Eligibility Criteria

Inclusion

  • Patients ≥ 18 years
  • Undergoing successful PCI (either ACS or elective PCI)
  • History of or newly diagnosed (\<72 hours after PCI/ACS) atrial fibrillation or flutter with a long-term (≥ 1 year) indication for OAC

Exclusion

  • Contra indication to edoxaban, aspirin or all P2Y12 inhibitors
  • Current indication for OAC besides atrial fibrillation/flutter (e.g. venous thromboembolism)
  • \<12 months after any stroke
  • CHADSVASc score ≥7
  • Moderate to severe mitral valve stenosis (AVA ≤1.5 cm2)
  • Mechanical heart valve prosthesis
  • Intracardiac thrombus or apical aneurysm requiring OAC
  • Poor LV function (LVEF \<30%) with proven slow-flow
  • History of intracranial haemorrhage
  • Active bleeding on randomization
  • History of intraocular, spinal, retroperitoneal, or traumatic intra-articular bleeding, unless the causative factor has been permanently resolved
  • Recent (\<1 month) gastrointestinal haemorrhage, unless the causative factor has been permanently resolved.
  • Known coagulopathy
  • Severe anaemia requiring blood transfusion or thrombocytopenia \<50 × 109/L
  • BMI \>40 or bariatric surgery
  • Kidney failure (eGFR \<15)
  • Active liver disease (ALT, ASP, AP \>3x ULN or active hepatitis A, B or C)
  • Active malignancy excluding non-melanoma skin cancer
  • Life expectancy \<1 year
  • Pregnancy or breast-feeding women

Key Trial Info

Start Date :

January 11 2023

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2027

Estimated Enrollment :

2000 Patients enrolled

Trial Details

Trial ID

NCT04436978

Start Date

January 11 2023

End Date

December 1 2027

Last Update

December 15 2023

Active Locations (20)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 5 (20 locations)

1

ASZ Aalst

Aalst, Belgium

2

UZ Antwerpen

Antwerp, Belgium

3

Imelda Ziekenhuis

Bonheiden, Belgium

4

UZ Brussel

Brussels, Belgium